AI Article Synopsis
- A 54-year-old woman with a history of polycystic kidney disease underwent renal transplantation in 1995 and developed skin lesions in 2002.
- In 2006, she was diagnosed with EBV-related posttransplant lymphoproliferative disease (PTLD) after a biopsy revealed diffuse large B cell lymphoma, leading to treatments like radiation and rituximab therapy.
- Despite worsening skin ulcers, modifying her immunosuppressive drugs and additional surgical intervention resulted in effective treatment, highlighting the need for careful management of skin symptoms associated with PTLD after transplantation.
Article Abstract
A 54-year-old woman was diagnosed as having polycystic kidney in 1990. Renal transplantation was performed in 1995. She received immunosuppressive therapy postoperatively. Skin lesion was recognized on the left leg in April 2002 and skin biopsy demonstrated diffuse large B cell lymphoma in March 2006. EBV-LMP, EBNA-2 and EBER were positive and she was diagnosed as having EBV-related posttransplant lymphoproliferative disease (PTLD). Radiation therapy and rituximab therapy were administered. The skin ulcer worsened and she was referred to our hospital. We reduced the dose of immunosuppressive drug and performed debridement of the ulcer, which responded well to treatment. PTLD presenting with skin involvement rarely manifests as lesions, and such lesions develop slowly, when they occur. PTLD presenting with skin involvement after transplantation must be treated.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Sequence Analysis of microRNAs Encoded by Simian Lymphocryptoviruses.
Viruses
December 2024
Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006, USA.
Lymphocryptoviruses (LCVs) are ubiquitous gamma-herpesviruses that establish life-long infections in both humans and non-human primates (NHPs). In immunocompromised hosts, LCV infections are commonly associated with B cell disorders and malignancies such as lymphoma. In this study, we evaluated simian LCV-encoded small microRNAs (miRNAs) present in lymphoblastoid cell lines (LCLs) derived from a Mauritian cynomolgus macaque () with cyLCV-associated post-transplant lymphoproliferative disease (PTLD) as well as the viral miRNAs expressed in a baboon () LCL that harbors CeHV12.
View Article and Find Full Text PDFLimited utility of Epstein-Barr virus (EBV) surveillance for predicting post-transplant lymphoproliferative disorders in adult EBV seropositive lung transplant recipients.
J Clin Virol
December 2024
Division of Infectious Diseases, Department of Medicine, Duke University, Durham, NC, USA. Electronic address:
Article Synopsis
- EBV DNAemia surveillance is used to prevent post-transplant lymphoproliferative disorder (PTLD) in lung transplant recipients (LTRs), but its effectiveness in adult seropositive patients is unclear.
- A study analyzed EBV viral loads in seropositive LTRs and compared levels between those who developed PTLD and those who didn't, revealing that peak viral loads were only significantly higher after PTLD was suspected.
- The study found low positive predictive values (PPVs) for moderate (14.7%) and high-grade (33.3%) EBV DNAemia in indicating risk for future PTLD, suggesting improved diagnostic approaches are needed.
TB survivors: why curing TB is sometimes not enough.
IJTLD Open
December 2024
Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri IRCCS, Tradate, Italy.
It is now well understood that the effect of TB does not always end when a patient completes a successful course of treatment. Successful treatment is by definition a microbiological cure, but people may continue to suffer the consequences of TB for months or years after treatment. For example, ongoing health challenges can present in the form of post-TB lung disease (PTLD), and there is a high incidence of TB-related symptoms associated with disability in other domains.
View Article and Find Full Text PDFAtypical presentations of primary lymphoproliferative processes in the central nervous system.
Radiologia (Engl Ed)
December 2024
Servicio de Radiología, Hospital Universitario Doce de Octubre, Madrid, Spain.
Central nervous system (CNS) involvement by lymphoproliferative disorders is rare and associated with a poor prognosis. CNS involvement can be exclusive, primary or appear in a secondary manner as part of a systemic process. The spectrum of involvement that we encounter is varied and neuroimaging plays a key role in diagnosis.
View Article and Find Full Text PDFAnti-RA33 Antibodies Are Present in Patients With Lyme Disease.
J Clin Rheumatol
November 2024
From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD.
Background/objective: To determine if anti-RA33 antibodies, which can be seen in early forms of inflammatory arthritis, are present in patients with Lyme arthritis (LA).
Methods: Anti-RA33 antibodies were tested using a commercially available assay in patients with LA (n = 47) and compared with patients with erythema migrans who returned to health (EM RTH, n = 20) and those with post-treatment Lyme disease (PTLD) (n = 50), characterized by noninflammatory arthralgia, as an observational comparative study utilizing Lyme-exposed patients from various original cohorts.
Results: We found that anti-RA33 was present in higher proportions of patients with LA (23.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!